NCT05624723View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

February 7, 2024

Study Completion Date

February 7, 2024

Conditions
Renal InsufficiencyKidney Diseases
Interventions
DRUG

INCB054707

INCB054707 75 mg will be administered orally

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

D-81241

Apex Gmbh, Munich

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT05624723 - Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis | Biotech Hunter | Biotech Hunter